Zomedica Pharmaceuticals Corp
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.1761
- Today's High:
- $0.18
- Open Price:
- $0.1761
- 52W Low:
- $0.15
- 52W High:
- $0.335
- Prev. Close:
- $0.18
- Volume:
- 2736238
Company Statistics
- Market Cap.:
- $185.11 million
- Book Value:
- 0.265
- Revenue TTM:
- $22.44 million
- Operating Margin TTM:
- -115.82%
- Gross Profit TTM:
- $13.65 million
- Profit Margin:
- -86.65%
- Return on Assets TTM:
- -5.9%
- Return on Equity TTM:
- -7.4%
Company Profile
Zomedica Pharmaceuticals Corp had its IPO on 2016-07-29 under the ticker symbol ZOM.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Zomedica Pharmaceuticals Corp has a staff strength of 85 employees.
Stock update
Shares of Zomedica Pharmaceuticals Corp opened at $0.18 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.18 - $0.18, and closed at $0.18.
This is a -0.67% slip from the previous day's closing price.
A total volume of 2,736,238 shares were traded at the close of the day’s session.
In the last one week, shares of Zomedica Pharmaceuticals Corp have slipped by -5.4%.
Zomedica Pharmaceuticals Corp's Key Ratios
Zomedica Pharmaceuticals Corp has a market cap of $185.11 million, indicating a price to book ratio of 0.7048 and a price to sales ratio of 11.0995.
In the last 12-months Zomedica Pharmaceuticals Corp’s revenue was $22.44 million with a gross profit of $13.65 million and an EBITDA of $-20766000. The EBITDA ratio measures Zomedica Pharmaceuticals Corp's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Zomedica Pharmaceuticals Corp’s operating margin was -115.82% while its return on assets stood at -5.9% with a return of equity of -7.4%.
In Q2, Zomedica Pharmaceuticals Corp’s quarterly earnings growth was a positive 0% while revenue growth was a positive 41.8%.
Zomedica Pharmaceuticals Corp’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.02 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Zomedica Pharmaceuticals Corp’s profitability.
Zomedica Pharmaceuticals Corp stock is trading at a EV to sales ratio of 4.258 and a EV to EBITDA ratio of -3.9324. Its price to sales ratio in the trailing 12-months stood at 11.0995.
Zomedica Pharmaceuticals Corp stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $274.78 million
- Total Liabilities
- $7.21 million
- Operating Cash Flow
- $23.32 million
- Capital Expenditure
- $1.93 million
- Dividend Payout Ratio
- 0%
Zomedica Pharmaceuticals Corp ended 2024 with $274.78 million in total assets and $0 in total liabilities. Its intangible assets were valued at $274.78 million while shareholder equity stood at $259.48 million.
Zomedica Pharmaceuticals Corp ended 2024 with $1.25 million in deferred long-term liabilities, $7.21 million in other current liabilities, 380973000.00 in common stock, $-148038000.00 in retained earnings and $63.98 million in goodwill. Its cash balance stood at $27.95 million and cash and short-term investments were $130.47 million. The company’s total short-term debt was $641,000 while long-term debt stood at $0.
Zomedica Pharmaceuticals Corp’s total current assets stands at $139.63 million while long-term investments were $11.92 million and short-term investments were $102.52 million. Its net receivables were $1.96 million compared to accounts payable of $6.14 million and inventory worth $3.63 million.
In 2024, Zomedica Pharmaceuticals Corp's operating cash flow was $23.32 million while its capital expenditure stood at $1.93 million.
Comparatively, Zomedica Pharmaceuticals Corp paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.18
- 52-Week High
- $0.335
- 52-Week Low
- $0.15
- Analyst Target Price
- $6
Zomedica Pharmaceuticals Corp stock is currently trading at $0.18 per share. It touched a 52-week high of $0.335 and a 52-week low of $0.335. Analysts tracking the stock have a 12-month average target price of $6.
Its 50-day moving average was $0.2 and 200-day moving average was $0.21 The short ratio stood at 16.24 indicating a short percent outstanding of 0%.
Around 142.3% of the company’s stock are held by insiders while 974.2% are held by institutions.
Frequently Asked Questions About Zomedica Pharmaceuticals Corp
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform and VetGuardian, a zero-touch vital signs remote monitoring system, as well as Revo Squared imaging platform comprising diagnostic imaging products and services for use in animal health. It also provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for the development of a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan.